BostonGene

We’re collaborating with Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, to validate blood- and bone marrow-based assays for hematological cancers. Find out more:  https://lnkd.in/eBZQMKk7

Join the BostonGene team for #WorldCBCDx on September 3-6! Michael Goldberg, VP of R&D, will present "Integrated Immune Profiling of Peripheral Blood and Tumor Tissue for Rational Stratification of Patients in Immunotherapy Trials." This session will cover identifying immunological signatures, profiling the immune system to determine patient status, and evaluating transcriptional profiles to uncover prognostic biomarkers for predicting drug response and guiding treatment decisions. Register today! https://world-cdx.com/

Last week, the Kidney Cancer Research Summit (#KCRS24), an annual meeting that brings together clinicians, researchers, research advocates, scientists, medical oncologists, industry professionals, and others, took place to discuss future collaboration efforts in kidney cancer research. Pavlos Msaouel, MD, PhD, an oncologist from MD Anderson, delivered a compelling presentation on the power of BostonGene in "decoding" the ultra-aggressive and challenging Renal Medullary Carcinoma (#RMC). Watch the presentation here! https://lnkd.in/eQmsGE2F

The EMERGE 2050 Webinar Series - Healthtech Talks launched yesterday with the exciting topic: "From Big Data to Bedside: Is AI Revolutionizing Cancer Treatment?" chaired by Dr. Sadyk Gusniev. Watch the recording below to hear from our expert speakers: Dr. Mussaad M. Al-Razouki (Operating Partner, Deerfield Management) on "AI in Healthcare - From Theory to Practice" Dr. Joe Lennerz, MD, PhD (Chief Scientific Officer, BostonGene) discussing "Precision Oncology Powered by AI - Transforming Cancer Care" Don't miss these insightful discussions! https://lnkd.in/dSfmyaky #EmergeWebinar #HealthtechTalk #AIinHealthcare #CancerTreatment #PrecisionOncology

Prostate cancer patient Brian McCloskey underwent extensive testing from BostonGene, including whole genome DNA sequencing, RNA sequencing and multiplex immunofluorescence. He also received our immunoprofiling test and evolutionary report, with primary and metastatic samples analyzed. Our tests identified new biomarkers, characterized his tumor microenvironment and compared current and previous results to reveal the progression of his cancer. Brian's doctor, Rana McKay, MD at UCSD, used these findings to craft a personalized treatment plan. This plan included a clinical trial with a two-drug combination: cabozantinib, targeting VEGF and the immune checkpoint inhibitor nivolumab (Opdivo). Read more below.

Meet BostonGene, an organization whose mission is to power healthcare’s transition to #PersonalizedMedicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce the overall cost of cancer care. Cancer Patient Lab is proud to showcase #BostonGene as a trusted Service Provider in our science-backed #oncology network. Our Goal: To empowering you with the information and support you need to get the best possible outcomes in your #CancerJourney. Learn more about BostonGene: https://bostongene.com ----------------------------------------------------------------------------- Cancer Patient Lab is a #501c3 non-profit organization. Our patient-led community is founded with a mission to help advanced cancer patients and their caregivers find better solutions for their cancer treatments. We utilize crowd-sourcing to offer patients access to trusted best-in-class service providers. This puts patients at the center of their care and leverages the collective community to help patients find their best treatments. With the accelerating pace of life sciences and the limited time of healthcare professionals to solve complex problems, we know that yesterday’s diagnostics or treatments may not be best-in-class today. Patients need trusted partners who can offer the best that science has to offer.

Meet us today at hubXchange's Immuno-Oncology Xchange Boston 2024! Be sure to attend the roundtable discussion, "Multiomic immune biomarker selection for novel IO response and toxicity assessment: tissue, blood, plasma, or all of the above?" led by Michael Goldberg, PhD, VP, Research & Development at BostonGene. This session will explore using immune biomarkers to enhance drug development and patient outcomes. The focus will be on current applications, technological advancements, novel approaches and necessary validation and regulatory processes, highlighting how these strategies can improve therapeutic results and personalize treatments. https://lnkd.in/ej7CAYTT

Meet us today at hubXchange's Immuno-Oncology Xchange Boston 2024! Be sure to attend the roundtable discussion, "Multiomic immune biomarker selection for novel IO response and toxicity assessment: tissue, blood, plasma, or all of the above?" led by Michael Goldberg, PhD, VP, Research & Development at BostonGene. This session will explore using immune biomarkers to enhance drug development and patient outcomes. The focus will be on current applications, technological advancements, novel approaches and necessary validation and regulatory processes, highlighting how these strategies can improve therapeutic results and personalize treatments. https://lnkd.in/ej7CAYTT

Great times at the Festival of Genomics in Boston with Nikki Petrich and BostonGene. The last 2 days have been filled with interesting conversations and sessions with domain experts in the field of genomics, biopharma, and biodata science. My favorite was the "genome dome" and the Helix of Love Link to the meeting: https://lnkd.in/eKj96EjV. Big props to Michael Adeniya the Managing director of Frontlinegenomics and his team for organizing this event. https://lnkd.in/eRAE8vVq Sidenote.... The Festival of Genomics also goes by "FOG", which will certainly fit the weather in London in January.... I presume... looking forward to seeing you in London https://lnkd.in/eS3GC5xH BostonGene #genomics #drugdevelopment #biomarker #precisionmedicine #precisiononcology #AI #diagnostics #imaging

We're excited to announce that our poster, done in collaboration with Jason A. Mouabbi, at #ASCO24 received the GRASP Advocate Choice Award! The study revealed the intricate heterogeneity of the tumor microenvironment (#TME) in invasive lobular carcinoma (#ILC) through bulk RNA-seq and spatial biology analyses, highlighting the importance of TME profiling in developing personalized treatments for ILC patients! https://lnkd.in/emwYQkQu